R. Michael Van Dam

Prof. Dr. R. Michael Van Dam

Crump Institute for Molecular Imaging and Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 90095 USA
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2004 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
JRJason P. Rolland
Jason P. Rolland
RDR. Michael Van Dam
R. Michael Van Dam
DSDerek A. Schorzman
Derek A. Schorzman
SQStephen R. Quake
Stephen R. Quake
JDJoseph M. DeSimone
Joseph M. DeSimone

21 August 2019 in Nature
Verified
Journal Article
Closed access
PDF file
JLJia Li
Jia Li
NHNoel S. Ha
Noel S. Ha
TLTingyi Liu
Tingyi Liu
RDR. Michael Van Dam
R. Michael Van Dam
CKChang-Jin Kim
Chang-Jin Kim

30 December 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PKPei Yuin Keng
Pei Yuin Keng
SCSupin Chen
Supin Chen
HDHuijiang Ding
Huijiang Ding
SSSaman Sadeghi
Saman Sadeghi
GSGaurav J. Shah
Gaurav J. Shah
RDR. Michael Van Dam
R. Michael Van Dam
We have developed an all-electronic digital microfluidic device for microscale chemical synthesis in organic solvents, operated by electrowetting-on-dielectric (EWOD). As an example of the principles, we demonstrate the multistep synthesis of [ 18 F]FDG, the most common radiotracer for positron emission tomography (PET), with high and reliable radio-fluorination efficiency of [ 18 F]FTAG (88 ± 7%, n = 11) and quantitative hydrolysis to [ 18 F]FDG (> 95%, n = 11). We furthermore show that batches of purified [ 18 F]FDG can successfully be used for PET imaging in mice and that they pass typical quality control requirements for human use (including radiochemical purity, residual solvents, Kryptofix, chemical purity, and pH). We report statistical repeatability of the radiosynthesis rather than best-case results, demonstrating the robustness of the EWOD microfluidic platform. Exhibiting high compatibility with organic solvents and the ability to carry out sophisticated actuation and sensing of reaction droplets, EWOD is a unique platform for performing diverse microscale chemical syntheses in small volumes, including multistep processes with intermediate solvent-exchange steps.

28 July 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JSJing Sun
Jing Sun
MMMichael D. Masterman-Smith
Michael D. Masterman-Smith
NGNicholas A. Graham
Nicholas A. Graham
JJJing Jiao
Jing Jiao
JMJack Mottahedeh
Jack Mottahedeh
HTHsian-Rong Tseng
Hsian-Rong Tseng
The clinical practice of oncology is being transformed by molecular diagnostics that will enable predictive and personalized medicine. Current technologies for quantitation of the cancer proteome are either qualitative (e.g., immunohistochemistry) or require large sample sizes (e.g., flow cytometry). Here, we report a microfluidic platform—microfluidic image cytometry (MIC)—capable of quantitative, single-cell proteomic analysis of multiple signaling molecules using only 1,000 to 2,800 cells. Using cultured cell lines, we show simultaneous measurement of four critical signaling proteins (EGFR, PTEN, phospho-Akt, and phospho-S6) within the oncogenic phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway. To show the clinical application of the MIC platform to solid tumors, we analyzed a panel of 19 human brain tumor biopsies, including glioblastomas. Our MIC measurements were validated by clinical immunohistochemistry and confirmed the striking intertumoral and intratumoral heterogeneity characteristic of glioblastoma. To interpret the multiparameter, single-cell MIC measurements, we adapted bioinformatic methods including self-organizing maps that stratify patients into clusters that predict tumor progression and patient survival. Together with bioinformatic analysis, the MIC platform represents a robust, enabling in vitro molecular diagnostic technology for systems pathology analysis and personalized medicine. Cancer Res; 70(15); 6128–38. ©2010 AACR.

21 October 2009 in Physics in Medicine & Biology
Verified
Journal Article
Closed access
JCJennifer S Cho
Jennifer S Cho
RTRichard Taschereau
Richard Taschereau
SOSebastian Olma
Sebastian Olma
KLKan Liu
Kan Liu
YCYi-Chun Chen
Yi-Chun Chen
ACArion F Chatziioannou
Arion F Chatziioannou
It has been observed that microfluidic chips used for synthesizing (18)F-labeled compounds demonstrate visible light emission without nearby scintillators or fluorescent materials. The origin of the light was investigated and found to be consistent with the emission characteristics from Cerenkov radiation. Since (18)F decays through the emission of high-energy positrons, the energy threshold for beta particles, i.e. electrons or positrons, to generate Cerenkov radiation was calculated for water and polydimethylsiloxane (PDMS), the most commonly used polymer-based material for microfluidic chips. Beta particles emitted from (18)F have a continuous energy spectrum, with a maximum energy that exceeds this energy threshold for both water and PDMS. In addition, the spectral characteristics of the emitted light from (18)F in distilled water were also measured, yielding a broad distribution from 300 nm to 700 nm, with higher intensity at shorter wavelengths. A photograph of the (18)F solution showed a bluish-white light emitted from the solution, further suggesting Cerenkov radiation. In this study, the feasibility of using this Cerenkov light emission as a method for quantitative measurements of the radioactivity within the microfluidic chip in situ was evaluated. A detector previously developed for imaging microfluidic platforms was used. The detector consisted of a charge-coupled device (CCD) optically coupled to a lens. The system spatial resolution, minimum detectable activity and dynamic range were evaluated. In addition, the calibration of a Cerenkov signal versus activity concentration in the microfluidic chip was determined. This novel method of Cerenkov radiation measurements will provide researchers with a simple yet robust quantitative imaging tool for microfluidic applications utilizing beta particles.

1 February 2010 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
AEArkadij M. Elizarov
Arkadij M. Elizarov
RDR. Michael Van Dam
R. Michael Van Dam
YSYoung Shik Shin
Young Shik Shin
HKHartmuth C. Kolb
Hartmuth C. Kolb
HPHenry C. Padgett
Henry C. Padgett
JHJames R. Heath
James R. Heath
An integrated elastomeric microfluidic device, with a footprint the size of a postage stamp, has been designed and optimized for multistep radiosynthesis of PET tracers. Methods: The unique architecture of the device is centered around a 5-μL coin-shaped reactor, which yields reaction efficiency and speed from a combination of high reagent concentration, pressurized reactions, and rapid heat and mass transfer. Its novel features facilitate mixing, solvent exchange, and product collection. New mixing mechanisms assisted by vacuum, pressure, and chemical reactions are exploited. Results: The architecture of the reported reactor is the first that has allowed batch-mode microfluidic devices to produce radiopharmaceuticals of sufficient quality and quantity to be validated by in vivo imaging. Conclusion: The reactor has the potential to produce multiple human doses of 18F-FDG; the most impact, however, is expected in the synthesis of PET radiopharmaceuticals that can be made only with low yields by currently available equipment.